Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France
Corinne Lévy, A. Werner, Alexis Rybak, Stéphane Béchet, Christophe Batard, Fréderic Hassid, Roxane Desandes, Bruno Frandji, Naïm Ouldali, Robert Cohen
Abstract
After the implementation of nirsevimab in 2023 in France as compared with 2022–2023, we found a 52.7%, (95% CI [46.4–58.9])decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.
Topics & Concepts
BronchiolitisMedicineAmbulatoryPediatricsProspective cohort studyPopulationInternal medicineEnvironmental healthRespiratory systemRespiratory viral infections researchViral Infections and Immunology ResearchTransplantation: Methods and Outcomes